CDC Advisory Committee Says Moderna COVID Shot Has Higher Risk of Myocarditis vs. Pfizer Shot
Posted on 02/05/2022
Myocarditis is an inflammation of the heart muscle that can result in serious health problems. A severe case can weaken the heart, which can lead to heart failure, abnormal heartbeat, and sudden death. Symptoms include chest pain, abnormal heartbeat, and shortness of breath.
Myocarditis events have been linked to a percentage of people receiving the COVID mRNA vaccines – both ones developed by Pfizer Inc. and Moderna, Inc. (ticker: MRNA). Pfizer and Moderna have liability protection from the U.S. government under the emergency use order.
On February 4, 2022, the CDC’s Advisory Committee on Immunization Practices, a panel of outsiders, had a debate on the risks of developing myocarditis after receiving Moderna’s or Pfizer’s vaccines. The committee concluded that Moderna’s two-dose COVID-19 vaccine is associated with a higher risk of heart inflammation than Pfizer’s. According to the CDC’s safety surveillance program, the risk of Myocarditis was higher following the second dose of Moderna’s vaccine in people ages 18 to 39. Public health authorities in Ontario found that the rate of myocarditis was five times higher for males ages 18 to 24 following the second dose of Moderna’s vaccine than Pfizer’s.
In January 2022, U.S. Senator Ron Johnson held a panel discussion with a group of doctors and medical experts questioning government policy and vaccine efficacy and safety.
Keywords: Moderna Therapeutics (Moderna).